Novavax, 5th COVID-10 vaccine approved in Australia – Archyde

CANBERRA, Australia (AP) – Australia on Thursday approved the COVID-19 vaccine developed by Novavax, the fifth available in the country.

The country has ordered 51 million doses of the US-made formula, marketed under the brand name Nuvaxovid, for its 26 million people. Those from Pfizer-BioNTech, AstraZeneca and Moderna are already being administered in Australia and Johnson and Johnson’s, Janssen, is approved, although the government has not bought any doses at the moment.

The Novavax vaccine will be available to unvaccinated people over the age of 18, but will not be used as a booster dose for the 95% of the population over the age of 16 who have already received two doses.

“Despite the massive proliferation of vaccines in this country, there are some people who have been waiting for Novavax, and it’s great that it’s finally been approved,” said John Skerritt, director of regulator The Therapeutic Goods Administration.

“Our dream is to turn that 95% into 97 or 98% in this country,” he added.

The protein-based vaccine is given in two doses three weeks apart.

Leave a Reply

Your email address will not be published.